Improvement of Metabolic Syndrome and Its Components in Patients Who Underwent Transsphenoidal Resection for Pituitary Adenoma

Overview

Journal Acta Neurochir (Wien)

Specialty Neurosurgery

Date 2024 Feb 16

PMID 38363400

Authors

A P Cortes-Contreras

A Salazar-Pigeon

J A Gonzalez-Almazan

R Flores-Rabasa

J L Navarro-Olvera

L A Mendez-Garcia

J D Carrillo-Ruiz

Affiliations

Soon will be listed here.

Abstract

Background: Pituitary adenomas (PA) are neoplasms of pituitary adenohypophyseal cell lineage, which are the third most common cause of brain tumors among adults. Due to hormone secretion, PAs are closely related to metabolic syndrome (MetS). However, the relationship between these two entities has been scarcely studied to date.

Purpose: This paper aims to evaluate changes in the metabolic status of patients with PA before and after surgical treatment and to look for differences in metabolic outcomes among patients according to the adenoma type and the surgery success rate.

Methods: We assessed patients with PA who went through transsphenoidal surgery for its treatment, documenting metabolic parameters before and after surgery, analyzed whole sample changes, and then stratified them according to adenoma type (nonfunctioning, somatotroph, lactotroph, and corticotroph), and surgery success (total resection, near-total resection, partial resection, subtotal resection).

Results: A total of 214 patients were enrolled for this study. The prevalence of MetS with AACE criteria went from 51.52% before surgery to 28.99% after surgery (P < 0.001). Hyperglycemia (HG) was the most beneficial component; it went from 56% pre-surgery to 40.51% post-surgery (P = 0.03). The total resection group had the best improvement, with a significant decrease of prevalence in MetS from 83 to 16% (P < 0.001), and every component, except hypoalphalipoproteinemia (HA): obesity went from 96 to 67% (P < 0.001), arterial hypertension (AH) 59 to 24% (P < 0.001), HG 74 to 23% (P < 0.001), and hypertriglyceridemia (HTG) from 81 to 54% (P < 0.001). According to MetS prevalence, there was no difference in the improvement according to PA type.

Conclusion: Surgical treatment in patients with PA is associated with MetS improvement.

References

Cetinkaya Altuntas S, Evran M, Sert M, Tetiker T . Markers of Metabolic Syndrome in Patients with Pituitary Adenoma: A Case Series of 303 Patients. Horm Metab Res. 2019; 51(11):709-713. DOI: 10.1055/a-1020-3992. View

Ausiello J, Bruce J, Freda P . Postoperative assessment of the patient after transsphenoidal pituitary surgery. Pituitary. 2008; 11(4):391-401. DOI: 10.1007/s11102-008-0086-6. View

Baba N, Kameda H, Nakamura A, Cho K, Nomoto H, Mitsuhashi T . Silent pituitary adenoma and metabolic disorders: obesity, abnormal glucose tolerance, hypertension and dyslipidemia. Endocr J. 2020; 68(2):195-200. DOI: 10.1507/endocrj.EJ20-0185. View

Ben-Jonathan N, Hugo E, Brandebourg T, LaPensee C . Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab. 2006; 17(3):110-6. DOI: 10.1016/j.tem.2006.02.005. View

Bloomgarden Z . Adiposity and diabetes. Diabetes Care. 2002; 25(12):2342-9. DOI: 10.2337/diacare.25.12.2342. View

Tang L, Cheng G, Xu Z . Association between estrogen receptor α gene (ESR1) PvuII (C/T) and XbaI (A/G) polymorphisms and hip fracture risk: evidence from a meta-analysis. PLoS One. 2014; 8(12):e82806. PMC: 3903335. DOI: 10.1371/journal.pone.0082806. View

Ciric I, Ragin A, Baumgartner C, Pierce D . Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery. 1997; 40(2):225-36; discussion 236-7. DOI: 10.1097/00006123-199702000-00001. View

Fode N, Laws E, NORTHCUTT R . Pituitary tumors and hypertension: implications for neurosurgical nurses. J Neurosurg Nurs. 1983; 15(1):33-5. DOI: 10.1097/01376517-198302000-00008. View

Harbeck B, Danneberg S, Rahvar A, Monig H, Haas C . Prevalence and Predictors of Overweight and Obesity in Patients with Pituitary Dysfunctions. Endocr Metab Immune Disord Drug Targets. 2016; 16(4):249-253. DOI: 10.2174/1871530316666161130160809. View

10.

Huang P . A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009; 2(5-6):231-7. PMC: 2675814. DOI: 10.1242/dmm.001180. View

11.

Joustra S, Claessen K, Dekkers O, van Beek A, Wolffenbuttel B, Pereira A . High prevalence of metabolic syndrome features in patients previously treated for nonfunctioning pituitary macroadenoma. PLoS One. 2014; 9(3):e90602. PMC: 3946551. DOI: 10.1371/journal.pone.0090602. View

12.

Leaes C, Fernandes M, Alves L, Araujo B, Rech C, Ferreira N . Assessment of Anthropometric and Physical Health Indicators before and after Pituitary Surgery in Patients with Nonfunctioning Pituitary Adenomas, Acromegaly, and Cushing Disease. Indian J Endocrinol Metab. 2019; 23(4):473-479. PMC: 6844162. DOI: 10.4103/ijem.IJEM_301_19. View

13.

Melmed S . Pituitary-Tumor Endocrinopathies. N Engl J Med. 2020; 382(10):937-950. DOI: 10.1056/NEJMra1810772. View

14.

Chyu K, Zhao X, Reyes O, Babbidge S, Dimayuga P, Yano J . Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-/-) mice. Biochem Biophys Res Commun. 2005; 338(4):1982-9. DOI: 10.1016/j.bbrc.2005.10.141. View

15.

Park S, Blumenthal J, Lee S, Georgiades A . Association of cortisol and the metabolic syndrome in Korean men and women. J Korean Med Sci. 2011; 26(7):914-8. PMC: 3124722. DOI: 10.3346/jkms.2011.26.7.914. View

16.

Perez-Lopez C, Palpan A, Saez-Alegre M, Zamarron A, Alfonso C, Alvarez-Escola C . Volumetric Study of Nonfunctioning Pituitary Adenomas: Predictors of Gross Total Resection. World Neurosurg. 2020; 147:e206-e214. DOI: 10.1016/j.wneu.2020.12.020. View

17.

Rabinowitz D, Zierler K . A METABOLIC REGULATING DEVICE BASED ON THE ACTIONS OF HUMAN GROWTH HORMONE AND OF INSULIN, SINGLY AND TOGETHER, ON THE HUMAN FOREARM. Nature. 1963; 199:913-5. DOI: 10.1038/199913a0. View

18.

Schwetz V, Librizzi R, Trummer C, Theiler G, Stiegler C, Pieber T . Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas. Metab Brain Dis. 2016; 32(1):155-161. PMC: 5566581. DOI: 10.1007/s11011-016-9882-2. View

19.

Vargas-Ortega G, Gonzalez-Virla B, Balcazar-Hernandez L, Nieto-Guzman O, Garrido-Mendoza A, Flores-Maya M . Cardiovascular Risk and Metabolic Syndrome Characteristics in Patients with Nonfunctional Pituitary Macroadenoma. Int J Endocrinol. 2018; 2018:2852710. PMC: 6129843. DOI: 10.1155/2018/2852710. View

20.

Zhang T, Li S, Bazzano L, He J, Whelton P, Chen W . Trajectories of Childhood Blood Pressure and Adult Left Ventricular Hypertrophy: The Bogalusa Heart Study. Hypertension. 2018; 72(1):93-101. PMC: 6002936. DOI: 10.1161/HYPERTENSIONAHA.118.10975. View